SOLV
$68.67
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Den...
Recent News
3 of Wall Street’s Favorite Stocks with Open Questions
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth
Solventum Corporation (NYSE:SOLV) is one of the cheap new stocks to buy now. On February 26, Solventum reported Q4 2025 financial results that exceeded expectations, despite a reported sales decline of 3.7% to $2 billion. This decrease was driven by the divestiture of the company’s Purification and Filtration business in September 2025. However, organic sales […]
A Look At Solventum (SOLV) Valuation After Earnings Beat Buyback Plan And Growth Guidance
Solventum (SOLV) is back in focus after reporting fourth quarter and full year 2025 earnings that topped Wall Street expectations, along with a new US$1b share repurchase plan and portfolio-expanding tuck-in acquisitions. See our latest analysis for Solventum. Despite upbeat earnings and new capital allocation plans, Solventum’s recent trading has been choppy, with a 1 day share price return of 3.56% decline and a 90 day share price return of 13.28% decline at US$74.20. The 1 year total...
Solventum Q4 Earnings Call Highlights
Solventum (NYSE:SOLV) executives said the company ended fiscal 2025 with “solid momentum” in its first full year as a standalone public company, pointing to improved organic sales growth, continued separation progress from 3M, and portfolio actions that included the sale of its Purification & Fi
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures.